Guardant Health announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research Annual Meeting, April 5-10 in San Diego. Multiple poster sessions will report on the utility of using the Guardant Infinity platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction. “We look forward to sharing new data at AACR, in particular studies demonstrating the potential for epigenomic analysis using the Guardant Infinity platform to advance cancer research,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “These presentations illustrate how epigenomics can unlock the mechanisms of cancer cell regulation that are invisible to genomic testing, allowing us to expand patient eligibility for clinical trials and contributing to targeted therapy development and better-informed patient care.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Revises Co-CEOs’ Compensation and Incentives
- Guardant Health’s ECLIPSE study data demonstrates efficacy of Shield blood test
- Guardant Health price target lowered to $30 from $40 at Piper Sandler
- Guardant Health price target lowered to $37 from $44 at TD Cowen
- Guardant Health price target lowered to $35 from $38 at BofA
